EUVIMEDEUVIMED entdecken
Crossref

Positive effect of erythromycin on ineffective oesophageal motility in laryngopharyngeal reflux patients: Room for a novel treatment?

Fienne Sime, David Tovmassian, Gregory L Falk

Clinical Physiology and Functional Imaging · 2025

DOI: 10.1111/cpf.12924 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Physiology and Functional Imaging, 2025. Verfasst von Fienne Sime und 2 weiteren Autor:innen. Beteiligte Einrichtung: Sydney Heartburn Clinic, Lindfield, New South Wales, Australia. Hauptthemen laut MEDLINE: Erythromycin, Laryngopharyngeal Reflux, Manometry, Esophagus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Laryngopharyngeal reflux (LPR) management guidelines are currently derived from the management of gastroesophageal reflux disease (GORD) which has been shown to be poorly effective in controlling symptoms for these patients. Erythromycin is a macrolide antibiotic that has been used extensively as a prokinetic agent for the gastrointestinal tract. The management of LPR with prokinetics is a novel therapy being investigated with regard to its effectiveness. The purpose of this pilot study was to observe the effect of erythromycin on oesophageal motility with high resolution manometry (HRM) to establish if further study is warranted regarding its utility in management.

Methods

Consecutive patients were retrospectively identified from a prospectively maintained database at a single centre of patients with findings suggestive of LPR who had also undergone HRM. These patients all received lifestyle modification and erythromycin 250 mg BD with repeat HRM after 6 weeks of therapy.

Results

16 patients met inclusion criteria. Mean age was 56.2 ± 14.9. Mean ineffective swallows were 54.38% ± 41.3% compared with 34.4% ± 35.2% pre and post‐erythromycin therapy ( p = 0.018). Mean distal contractile integral at baseline was 793.61 ± 854.96 mmHg at baseline increasing to 1347 ± 1094.73 mmHg after erythromycin therapy ( p = 0.013). IRP also showed improvement from 8.99 ± 7.58 increasing to 10.93 ± 7.9 mmHg ( p = 0.045). Subgroup analysis of patients with ineffective oesophageal motility reinforced above findings as well as increase in the amount of ‘normal’ peristalsis.

Conclusion

This pilot study shows early evidence that erythromycin improves oesophageal motility. Further study is warranted to explore these findings in more detail.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErythromycinLaryngopharyngeal RefluxManometryEsophagusGastrointestinal AgentsHumansFemaleMiddle AgedPilot ProjectsMaleRetrospective StudiesAgedTreatment OutcomeAdultDatabases, FactualTime FactorsEsophageal Motility DisordersDeglutition

Stichwörter der Autor:innen

erythromycinlaryngopharyngealmotilityoesophagealreflux

Substanzen

ErythromycinGastrointestinal Agents

Autor:innen und Institutionen

  • Sydney Heartburn Clinic, Lindfield, New South Wales, Australia.
  • University of Sydney, Camperdown, New South Wales, Australia.

Zitieren

APA

Sime, F., Tovmassian, D., & Falk, G. L. (2025). Positive effect of erythromycin on ineffective oesophageal motility in laryngopharyngeal reflux patients: Room for a novel treatment?. Clinical Physiology and Functional Imaging. https://doi.org/10.1111/cpf.12924

Vancouver

Sime F, Tovmassian D, Falk GL. Positive effect of erythromycin on ineffective oesophageal motility in laryngopharyngeal reflux patients: Room for a novel treatment?. Clinical Physiology and Functional Imaging. 2025. doi:10.1111/cpf.12924

BibTeX
@article{Sime2025,
  author = {Sime, Fienne and Tovmassian, David and Falk, Gregory L},
  title = {Positive effect of erythromycin on ineffective oesophageal motility in laryngopharyngeal reflux patients: Room for a novel treatment?},
  journal = {Clinical Physiology and Functional Imaging},
  year = {2025},
  doi = {10.1111/cpf.12924}
}
Kostenlos starten →